Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors
This was the stock's third consecutive day of losses.
Guggenheim lowers Regeneron price target, says selloff ‘overdone’
Guggenheim lowered the firm’s price target on Regeneron (REGN) to $950 from $1,200 and keeps a Buy rating on the shares. The firm, which is ...
Regeneron announces FDA acceptance of BLA for linvoseltamab
Regeneron (REGN) announced that the U.S. Food and Drug Administration has accepted for review the resubmission of the Biologics License ...
Dow Jones Futures: Nvidia Faces This Critical Test At Key Level; Astera Dives On Earnings
Nvidia stock rallied to a critical level Monday, with Fed Chairman Jerome Powell set to testify in front of Congress.
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors
This was the stock's second consecutive day of losses.